Duality Biotherapeutics, Inc. (9606) Stock Statistics & Valuation Metrics

Duality Biotherapeutics, Inc. has a market cap or net worth of HK$23.15B. The enterprise value is HK$18.69B.

Duality Biotherapeutics, Inc. has 90,137,710 shares outstanding. The number of shares has decreased by -2.65% in one year.

Duality Biotherapeutics, Inc.’s return on equity (ROE) is -1.04 and return on invested capital (ROIC) is -13.93%.

The current PE Ratio of Duality Biotherapeutics, Inc. is ―. Duality Biotherapeutics, Inc.’s PEG ratio is -0.03.

In the last 12 months, Duality Biotherapeutics, Inc. had revenue of 1.80B and earned -2.53B in profits. Earnings per share was -38.79.

In the last 12 months, operating cash flow was 855.12M and capital expenditures -10.06M, giving a free cash flow of 845.06M billion.

Duality Biotherapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Duality Biotherapeutics, Inc. upcoming earnings date is Mar 23, 2026, Before Open (Confirmed).

Duality Biotherapeutics, Inc. as a current ratio of 3.61, with Debt / Equity ratio of 6.17%

In the past 12 months, Duality Biotherapeutics, Inc. has paid 0.00 in taxes.

Duality Biotherapeutics, Inc. EV to EBITDA ratio is -40.26, with an EV/FCF ratio of 89.99.

Duality Biotherapeutics, Inc. has HK$3.70B in cash and marketable securities with HK$67.89M in debt, giving a net cash position of HK$3.63B billion.

Gross margin is 41.83%, with operating margin of -23.08%, and net profit margin of -140.13%.

The average price target for Duality Biotherapeutics, Inc. is HK$445.52, which is 11.43% higher than the current price. The consensus rating is Strong Buy